Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy - Lee, Heng-Huan; Wang, Ying-Nai; Xia, Weiya; Chen, Chia-Hung; Rau, Kun-Ming; Ye, Leiguang; Wei, Yongkun; Chou, Chao-Kai; Wang, Shao-Chun; Yan, Meisi; Tu, Chih-Yen; Hsia, Te-Chun; et al. (Cancer cell, 2019)
Keywords: A549 Cells; Antibodies - immunology; Antibody Specificity; antibody-based detection; Antineoplastic Agents, Immunological - therapeutic use; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - immunology; B7-H1 Antigen - metabolism; biomarker; Clinical Decision-Making; False Negative Reactions; Glycosylation; glycosylation/deglycosylation; heterogeneity/homogeneity; Humans; immune checkpoint; Immunohistochemistry; immunotherapy; Jurkat Cells; MCF-7 Cells; Neoplasms - drug therapy; Neoplasms - immunology; Neoplasms - metabolism; Patient Selection; PD-1; PD-L1; Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase - metabolism; Predictive Value of Tests; Protein Processing, Post-Translational; Reproducibility of Results; Specimen Handling - methods; THP-1 Cells; glycosylation/deglycosylation; immune checkpoint; immunotherapy; PD-L1; immunohistochemistry; biomarker; PD-1; antibody-based detection; heterogeneity/homogeneity